Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fosmidomycin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 1/20 | 0.46 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.41 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fosmidomycin SCHEMBL301404 | 0.98 | TYMS (0.48) | TYMSS1PR2S1PR1S1PR3S1PR5 | |
| Fosmidomycin SCHEMBL11438018 | 0.96 | TYMS (0.46) | TYMSS1PR2S1PR1S1PR3S1PR5 | |
| Fosmidomycin SCHEMBL11434157 | 0.90 | LMNA (0.50) | TYMS | |
| Fosmidomycin SCHEMBL14485270 | 0.90 | S1PR2 (0.50) | S1PR2S1PR1S1PR3S1PR5 | |
| SCHEMBL10795849 | 0.89 | LPAR3 (0.45) | TYMSS1PR2S1PR1S1PR3S1PR5 | |
| SCHEMBL11313004 | 0.89 | LPAR3 (0.45) | TYMSS1PR2S1PR1S1PR3S1PR5 | |
| Fosmidomycin SCHEMBL10824609 | 0.87 | ALDH1A1 (0.48) | S1PR2S1PR1S1PR3S1PR5 | |
| SCHEMBL4322762 | 0.84 | TYMS (0.39) | TYMS | |
| SCHEMBL18161031 | 0.81 | GABBR2 (0.45) | — | |
| Fosmidomycin SCHEMBL10350781 | 0.80 | S1PR2 (0.35) | S1PR2S1PR1S1PR3S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4210635-A | A PHOSPHONIC ACID DERIVATIVE AND AN ANTIBIOTIC | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-07-01 | — | — | US | claimed |
| US-7638505-B2 | Organophosphoric derivatives useful as anti-parasitic agents | UNIVERSITEIT GENT (BE) | 2009-12-29 | — | — | US | disclosed |
| US-20080312190-A1 | Such as 3-(N-hydroxyacetamido)-1-(3,4-dichlorophenyl)propylphosphonic acid; Antimalaria agents | UNIVERSITEIT GENT (BE) | 2008-12-18 | — | — | US | disclosed |
| EP-1963344-A1 | ORGANOPHOSPHORIC DERIVATIVES USEFUL AS ANTI-PARASITIC AGENTS | UNIVERSITEIT GENT (BE) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007071453-A1 | ORGANOPHOSPHORIC DERIVATIVES USEFUL AS ANTI-PARASITIC AGENTS | UNIVERSITEIT GENT (BE) | 2007-06-28 | — | — | WO | disclosed |
| US-20040082549-A1 | Use of organophosphorus compounds for the therapeutic and prophylactic treatment of infections | JOMAA HASSAN (DE) | 2004-04-29 | — | — | US | disclosed |
| US-6680308-B1 | ADMINISTERING N-(FORMYL OR ACETYL)-N-HYDROXYLAMINO)-ALKYLPHOSPHONIC ACID DERIVATIVE AS VIRICIDE, PARASITICIDE OR FUNGICIDE | BIOAGENCY AG (DE) | 2004-01-20 | — | — | US | disclosed |
| EP-1141379-A1 | SCREENING FOR INHIBITORS OF TERPENOIDS BIOSYNTHESIS | Bacher, Adelbert (DE) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000036138-A1 | SCREENING FOR INHIBITORS OF TERPENOIDS BIOSYNTHESIS | BACHER ADELBERT (DE) | 2000-06-22 | — | — | WO | disclosed |
| US-5002602-A | Ametryn | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-03-26 | — | — | US | disclosed |
| US-4846872-A | FOSMIDOMYCIN, AMETRYN, DIURON | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312190-A1 | Such as 3-(N-hydroxyacetamido)-1-(3,4-dichlorophenyl)propylphosphonic acid; Antimalaria agents | SUB1, CBR1, NAT1 | TYMS 4108/4885S1PR2 992/4885S1PR1 480/4885 |
| US-20040082549-A1 | Use of organophosphorus compounds for the therapeutic and prophylactic treatment of infections | PON1, DDT, GPX1 | TYMS 1748/4885S1PR2 2251/4885S1PR1 998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.